Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-01-28
2004-03-02
Killos, Paul J. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S547000, C514S117000, C514S121000, C514S124000, C514S161000, C514S420000, C514S570000, C514S568000
Reexamination Certificate
active
06699902
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel acetyloxymethyl esters. The invention further relates to use of those acetyloxymethyl esters in the treatment of cancer and other proliferative diseases, hemoglobinopathies and inherited metabolic disorders and to treat or ameliorate various other illnesses and conditions, such as by hematopoietic stimulation. The present invention also relates to methods for using the disclosed compounds in the inhibition of histone deacetylase.
BACKGROUND INFORMATION
Histones are unique proteins in the nucleus of a cell. DNA is wound around a complex of histones to form nucleosomes. As such, histones are an integral structural element of the chromatin material. The histones complexed with the DNA are susceptible to a range of chemical modifications, one of which is acetylation, and the reverse of which is deacetylation. Acetylation of histone protein is believed to facilitate transcription of the DNA, thereby enhancing correlating with gene expression. Histone deacetylase is believed to reverse the process that represses gene expression. Histone dynamics are regulated by two enzymes--histone acetyl transferase and histone deacetylase.
Hyperacetylation due to inhibition of histone deacetylation, and the resulting expression of a latent gene, have been observed or proposed to occur in numerous inherited metabolic diseases and in cancer. The inhibition of histone deacetylase is believed to activate an otherwise dormant fetal gene, which serves as a redundant or back-up gene. Pharmacological inhibition of histone deacetylase, therefore, is believed to induce the expression of represser genes in cancer tissue, inhibit the expression of tumor-promoting genes, and induce the expression of the redundant or back-up gene in patients suffering from various metabolic and hematological diseases. Thus, inhibition of histone deacetylase is proposed to slow the growth of neoplastic cells and/or reverse the deficient process of various metabolic and hematological diseases. Inhibition of histone deacetylase is also believed to play a role in antiprotozoal activity.
Trichostatin is the most potent inhibitor of histone deacetylase observed so far, but due to various drawbacks, such as availability of the material, has not been pursued.
Butyric acid is a natural product that has been known for several decades to be an effective differentiating and antiproliferative agent in a wide spectra of neoplastic cells in vitro. For example, butyric acid has been reported to induce cellular and biochemical changes in cancer cells, to induce apoptosis, and to increase the expression of transfected DNA, although the mechanism of action of butyric acid is unknown. Increased histone acetylation following treatment with butyric acid has been correlated with changes in transcriptional activity and at differentiated states of cells. Butyric acid and its salts, however, have shown low potency in both in vitro assays and clinical trials, and thus require large doses to achieve even minimal therapeutic effects. This can lead to fluid overload and mild alkalosis.
The present invention is directed to acetyloxymethyl ester compounds, and methods for using the same, that have also been found to inhibit histone deacetylase. The present compounds show significantly greater activity than butyric acid or its salts. That acetyloxymethyl esters such as those of the present invention have the ability to inhibit histone deacetylase has been previously unreported in the art.
SUMMARY OF THE INVENTION
The present invention relates to novel acetyloxymethyl esters as described below. The compounds are useful in the inhibition of histone deacetylase.
The present invention therefore further relates to methods of treating a patient for an illness, particularly wherein the illness is one in which histone deacetylase inhibition would be beneficial. Examples include cancer, hemoglobinopathies and inherited metabolic disorders. Other illnesses and conditions that can be treated according to the present invention are discussed herein. In the case of histone deacetylase inhibition, the present compounds are believed to function by chelating the zinc ion at the active site of histone deacetylase; the inventor does not wish to be bound by this mechanism, however.
It is therefore an aspect of the invention to provide novel acetyloxymethyl esters.
Another aspect of the invention provides methods for treating a patient using acetyloxymethyl esters.
A method for inhibiting histone deacetylase in a patient is also an aspect of the present invention.
These and other aspects of the invention will be apparent upon reviewing the attached specification and appended claims.
REFERENCES:
patent: 3089883 (1963-05-01), Dohr et al.
patent: 4900478 (1990-02-01), Gross
patent: 5055588 (1991-10-01), Takase et al.
patent: 5158773 (1992-10-01), Gross
patent: 5173506 (1992-12-01), Neustadt et al.
patent: 5200553 (1993-04-01), Nudelman et al.
patent: 5569675 (1996-10-01), Rephaeli et al.
patent: 5574097 (1996-11-01), Klaveness et al.
patent: 5626855 (1997-05-01), Philippe
patent: 5667962 (1997-09-01), Brunengraber et al.
patent: 5710176 (1998-01-01), Rephaeli et al.
patent: 5710279 (1998-01-01), Lantzsch et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 6040342 (2000-03-01), Rephaeli et al.
patent: 6071923 (2000-06-01), Nudelman et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6110970 (2000-08-01), Nudelman et al.
patent: 32 07 241 (1983-09-01), None
patent: 1 138 745 (1969-01-01), None
patent: 2 043 639 (1980-10-01), None
patent: 1 579 531 (1980-11-01), None
patent: 2 048 857 (1980-12-01), None
patent: 2 097 786 (1982-11-01), None
patent: 57 179190 (1982-11-01), None
patent: 60 139682 (1985-07-01), None
patent: WO01/90136 (1985-07-01), None
patent: WO 98/00127 (1998-01-01), None
patent: WO98/39965 (1998-09-01), None
patent: WO98/40065 (1998-09-01), None
patent: WO 98/40065 (1998-09-01), None
Lombardi et al., “Total Synthesis of Thia Analogues of Clavulanic Acid,” Tetrhedron Letters, 39, 1979, 3777-3780.
Foglio et al., “Synthesis of Optically Active (5R)-2-Penem-3-carboxylates form penicillanic Acide Derivatives: New Potent Anti-bacterial Agents,” J.C.S. Chem. Commun. 2, 1980, 70-71.
Drew et al., “Antifertility Activity of N-Protected Glycine Activated Esters,” J. Pharma. Sci., 70, 1981, 60-63.
Longo et al., “Total Synthesis and Antibacterial Activity of Some 6-Ethyl-2-penem Derivatives,”gazz. Chim. Ital., 111, 1981, 371-377.
Alpegiani et al., “Synthesis of 2-(Heterocyclythiomethyl)Penems,” Gazz. Chim. Ital., 114, 1984, 319-324.
Battistini et al., “Synthesis of New Penem Derivatives: N-Substituted Analogs of FCE 22101,” Heterocycles, 23, 1985, 1929-1932.
Heilporn et al., “Synthesis of BAPTA-AM Analogues Capable of Enhancing the Vascular Production of Prostacyclin,” Bull. Soc. Chim. Belg., 104, 1994, 309-319.
Salazar et al., “Optically-active Dihydropyridines via Lipase-catalyzed Enantioselective Hydrolysis,” Tetrahedron: Asymmetry, 6, 1995, 2917-2920.
Lan-Hargest Hsuan-Yin
Wiech Norbert L.
Beacon Laboratories, Inc.
Fish & Richardson P.C.
Killos Paul J.
Reyes Hector M
LandOfFree
Acetyloxymethyl esters and methods for using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acetyloxymethyl esters and methods for using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acetyloxymethyl esters and methods for using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3214010